Rimeporide in Duchenne presented at the 20th WMS Congress
EspeRare presented the “Development of Rimeporide, a sodium-hydrogen exchanger inhibitor, as a therapy for Patients with Duchenne Muscular Dystrophy” at the 20th International Congress of the World Muscle Society in Brighton from 30th September to 4th October 2015.
Click on picture to view
For more information on the WMS Congress click here
As a private non-for-profit organisation, we strive to uncover the potential of existing molecules to address severe therapeutic unmet needs in rare diseases, thus giving better chances to existing drugs to reach these underserved patients.